CEBP CTRC-AACR San Antonio Breast Cancer Symposium 09 AM Call for Abstracts w/deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tangrea, J. A.
Right arrow Articles by Helsel, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tangrea, J. A.
Right arrow Articles by Helsel, W. E.

Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 4 325-330, Copyright © 1992 by American Association for Cancer Research


ARTICLES

Patients' perceptions on participation in a cancer chemoprevention trial

JA Tangrea, ME Adrianza and WE Helsel
Cancer Prevention Studies Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892.

The perceptions of patients regarding the benefits, disadvantages, and importance of their participation in a long-term cancer chemoprevention trial, the Isotretinoin-Basal Cell Carcinoma Prevention Trial, were assessed through a questionnaire mailed at the conclusion of the 3-year treatment period of the trial. Responses were evaluated overall, as well as within subgroups defined by sex, age, education level, treatment group, presence of side effects, and the number of skin biopsies performed during the 3-year intervention phase. Overall, "careful medical follow-up received" (43%) and "being part of a research effort" (24%) were the most frequently cited important benefits, while the "amount of time taken to attend clinic" (32%) and "side effects" (20%) were the most frequently cited unpleasant aspects of trial participation. Most surveyed patients viewed the study as "very or extremely important" to their general health (62%) and their skin cancer condition (88%) and, as a result of participation, felt "much or somewhat better" physically (52%). The majority indicated that they would "definitely or probably" be willing to take part in another research study (79%) and take the study medication, if it were shown to be effective in the trial (78%). Overall and subgroup data provide important insights into patient motivations and attitudes regarding cancer chemoprevention trial participation, adherence, and satisfaction.


This article has been cited by other articles:


Home page
Med Decis MakingHome page
C. T. Veit
A Single Mathematical Model Predicts Physicians' Recommendations and Postmenopausal Women's Decisions to Participate in a Clinical Trial to Prevent Breast Cancer or Coronary Heart Disease
Med Decis Making, August 1, 2004; 24(4): 330 - 350.
[Abstract] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. A. Sample, P. S. Sinicrope, M. J. Wargovich, and F. A. Sinicrope
Post-Study Aspirin Intake and Factors Motivating Participation in a Colorectal Cancer Chemoprevention Trial
Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 281 - 285.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.